Article Type
Changed
Mon, 07/17/2023 - 15:39

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

 

Publications
Topics
Sections

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

 

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Breast Cancer July 2023
Gate On Date
Tue, 12/20/2022 - 14:15
Un-Gate On Date
Tue, 12/20/2022 - 14:15
Use ProPublica
CFC Schedule Remove Status
Tue, 12/20/2022 - 14:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article